The Motley Fool calls AbbVie the more sensible 2026 buy on valuation, although Eli Lilly is growing faster on demand for weight-loss and diabetes drugs. Lilly’s forward P/E and price-to-sales ratios are 24.8 and 13.2, versus 16.4 and 7.3 for AbbVie.
FY2025 figures cited in the article show Lilly revenue of about $65.2 billion, up 45%, and net income of $20.6 billion; AbbVie had $61.2 billion in revenue, up 9%, and $4.3 billion in net income. The article projects 2026 revenue of $85.2 billion for Lilly and $67.2 billion for AbbVie, with net income estimates of nearly $31 billion and $14.6 billion, respectively.
AbbVie faces reliance on Skyrizi and Rinvoq, biosimilar competition, and Inflation Reduction Act pricing pressure on Botox and Vraylar through 2028. Lilly faces payer pricing pressure and dependence on third-party suppliers, particularly in China. The valuation data are from Financial Modeling Prep and may differ across providers.
